Post-translational modification of Mediator 1(MED1) T1032 phosphorylation, which was regulated by PI3K/AKT signaling pathway [41], promoted the expression of UBE2C in prostate cancer and enhanced the role of UBE2C in promoting the proliferation of prostate cancer and in driving prostate cancer progression. This evidence concerns the gene MED1 and prostate cancer.